[{"id":"2f59ed54-b06e-4d43-9212-6877b8a1fbe8","acronym":"","url":"https://clinicaltrials.gov/study/NCT07470073","created_at":"2026-03-28T01:44:17.302Z","updated_at":"2026-03-28T01:44:17.302Z","phase":"Phase 1","brief_title":"A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Kinetics of Universal Car-t Cell Injection in CD19 and / or CD20 Positive Relapsed / Refractory B-cell Acute Lymphoblastic Leukemia in Adolescents, Children and Adults","source_id_and_acronym":"NCT07470073","lead_sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2026-03-13"},{"id":"8058c94b-0d21-42b2-b6cf-b07e05abfcb1","acronym":"PRO00037171","url":"https://clinicaltrials.gov/study/NCT04186520","created_at":"2021-07-05T17:26:53.958Z","updated_at":"2025-02-25T14:15:30.805Z","phase":"Phase 1/2","brief_title":"CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies","source_id_and_acronym":"NCT04186520 - PRO00037171","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR-20/19-T Cells"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 05/18/2020","start_date":" 05/18/2020","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-18"},{"id":"52a20f08-fb55-44a8-b556-28ccbdd505e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05421663","created_at":"2022-06-16T15:00:08.321Z","updated_at":"2025-02-25T16:39:05.573Z","phase":"Phase 1","brief_title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05421663","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prizloncabtagene autoleucel (JNJ-4496)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 12/29/2028","study_completion_date":" 12/29/2028","last_update_posted":"2025-02-06"},{"id":"5721b478-7256-41e9-bdb4-f8b5fa921a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05418088","created_at":"2022-06-14T21:56:15.500Z","updated_at":"2025-02-25T17:01:57.164Z","phase":"Phase 1","brief_title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05418088","lead_sponsor":"Sumithira Vasu","biomarkers":" CD20 • CD19 • CD22","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-02-03"},{"id":"ad11f149-0ac3-4e5e-9a2c-090277fc61cc","acronym":"CRC-403","url":"https://clinicaltrials.gov/study/NCT05169489","created_at":"2021-12-27T15:54:15.732Z","updated_at":"2025-02-25T17:01:36.333Z","phase":"Phase 1/2","brief_title":"A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)","source_id_and_acronym":"NCT05169489 - CRC-403","lead_sponsor":"Regeneron Pharmaceuticals","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bbT369"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/24/2022","start_date":" 01/24/2022","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-03"},{"id":"62643025-1b9c-4a89-a9ab-1626e60edfc3","acronym":"MPCT-012L","url":"https://clinicaltrials.gov/study/NCT05826535","created_at":"2023-04-24T14:04:02.070Z","updated_at":"2025-02-25T14:52:30.983Z","phase":"Phase 1/2","brief_title":"Study of IMPT-314 in R/R Aggressive B-cell NHL","source_id_and_acronym":"NCT05826535 - MPCT-012L","lead_sponsor":"ImmPACT Bio","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e rondecabtagene autoleucel (LYL314)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-01-14"},{"id":"63409644-83e7-4992-90f5-2ef1af04c65d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06532643","created_at":"2025-02-25T20:21:51.680Z","updated_at":"2025-02-25T20:21:51.680Z","phase":"Phase 1","brief_title":"Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma","source_id_and_acronym":"NCT06532643","lead_sponsor":"Shanghai First Song Biotechnology Co., LTD","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/24/2023","start_date":" 08/24/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-09-19"},{"id":"d6470e31-1ef9-400d-8e4a-687104d9ddb3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03277729","created_at":"2021-01-18T16:11:11.702Z","updated_at":"2024-07-02T16:34:26.876Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas","source_id_and_acronym":"NCT03277729","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" BCL2","pipe":" | ","alterations":" CD20 expression","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • MB-106"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 12/05/2017","start_date":" 12/05/2017","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 11/16/2037","study_completion_date":" 11/16/2037","last_update_posted":"2024-06-12"},{"id":"06e22114-2e9b-44ef-aeef-5965af238d91","acronym":"","url":"https://clinicaltrials.gov/study/NCT06014762","created_at":"2023-08-28T14:08:43.980Z","updated_at":"2024-07-02T16:34:59.518Z","phase":"Phase 1","brief_title":"P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies","source_id_and_acronym":"NCT06014762","lead_sponsor":"Poseida Therapeutics, Inc.","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RG6540 • rimiducid (AP1903)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 03/01/2029","primary_completion_date":" 03/01/2029","study_txt":" Completion: 03/01/2041","study_completion_date":" 03/01/2041","last_update_posted":"2024-06-03"},{"id":"3a3c09ba-f512-4df6-b272-3d719b2056f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04036019","created_at":"2021-01-18T19:48:18.141Z","updated_at":"2024-07-02T16:35:00.627Z","phase":"Phase 1","brief_title":"A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy","source_id_and_acronym":"NCT04036019","lead_sponsor":"Shanghai Tongji Hospital, Tongji University School of Medicine","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-9530"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 06/20/2022","primary_completion_date":" 06/20/2022","study_txt":" Completion: 06/20/2022","study_completion_date":" 06/20/2022","last_update_posted":"2024-05-28"},{"id":"41b868a7-e7be-446b-8235-fde40165cb18","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292898","created_at":"2022-03-23T13:53:39.110Z","updated_at":"2024-07-02T16:35:03.931Z","phase":"Phase 1","brief_title":"A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT05292898","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • LCAR-AIO"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-05-14"},{"id":"f8623cc4-62f7-4b2d-92a3-b96307060fe0","acronym":"CARMA-01","url":"https://clinicaltrials.gov/study/NCT06002659","created_at":"2023-08-21T14:08:59.477Z","updated_at":"2024-07-02T16:35:04.590Z","phase":"Phase 1/2","brief_title":"CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study)","source_id_and_acronym":"NCT06002659 - CARMA-01","lead_sponsor":"Uppsala University","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • ELC-301"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 05/01/2024","start_date":" 05/01/2024","primary_txt":" Primary completion: 12/30/2027","primary_completion_date":" 12/30/2027","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2024-05-09"},{"id":"099b5bf4-7bd1-4b6b-9199-1c53110e04ad","acronym":"DALY 2-EU","url":"https://clinicaltrials.gov/study/NCT04844866","created_at":"2021-04-14T11:52:59.944Z","updated_at":"2024-07-02T16:35:06.971Z","phase":"Phase 2","brief_title":"Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients","source_id_and_acronym":"NCT04844866 - DALY 2-EU","lead_sponsor":"Miltenyi Biomedicine GmbH","biomarkers":" BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 08/18/2021","start_date":" 08/18/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2024-04-30"},{"id":"8dda46df-1947-4289-9d30-b835dca6e2d3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03870945","created_at":"2021-01-18T19:05:14.371Z","updated_at":"2024-07-02T16:35:06.813Z","phase":"Phase 1/2","brief_title":"Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)","source_id_and_acronym":"NCT03870945","lead_sponsor":"Miltenyi Biomedicine GmbH","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zamtocabtagene autoleucel (MB-CART2019.1)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/25/2019","start_date":" 02/25/2019","primary_txt":" Primary completion: 12/17/2020","primary_completion_date":" 12/17/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-04-30"},{"id":"48d1c422-cd06-4d80-878d-98ad6d3840e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03664635","created_at":"2021-01-18T17:58:55.471Z","updated_at":"2024-07-02T16:35:08.135Z","phase":"Phase 1/2","brief_title":"MB-CART20.1 Lymphoma","source_id_and_acronym":"NCT03664635","lead_sponsor":"Miltenyi Biomedicine GmbH","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-CART20.1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 09/25/2018","start_date":" 09/25/2018","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-04-23"},{"id":"24c3c78a-e1db-479c-9eeb-d51b3073b8a7","acronym":"r/r B-NHL","url":"https://clinicaltrials.gov/study/NCT06364852","created_at":"2024-04-15T18:25:43.339Z","updated_at":"2024-07-02T16:35:09.799Z","phase":"Phase 1","brief_title":"An Evaluation of LY007 Cell Injection for r/r B-NHL","source_id_and_acronym":"NCT06364852 - r/r B-NHL","lead_sponsor":"Ruijin Hospital","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY007"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/25/2021","start_date":" 12/25/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-04-15"},{"id":"a9929cf7-40a1-4942-a4c2-1a9b6e8d511b","acronym":"NatHaLi-01","url":"https://clinicaltrials.gov/study/NCT05607420","created_at":"2022-11-07T13:56:26.754Z","updated_at":"2024-07-02T16:35:16.800Z","phase":"Phase 1/2","brief_title":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05607420 - NatHaLi-01","lead_sponsor":"Cellectis S.A.","biomarkers":" BCL2 • BCL6 • CD22","pipe":" | ","alterations":" CD20 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • etivelcabtagene erigedleucel (UCART20x22)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-03-01"},{"id":"099bccbb-36d2-4595-985a-23305468fb81","acronym":"r/r B-NHL","url":"https://clinicaltrials.gov/study/NCT06279611","created_at":"2024-02-29T02:32:51.155Z","updated_at":"2024-07-02T16:35:17.125Z","phase":"Phase 1","brief_title":"An Evaluation of LY007 Cell Injection for r/r B-NHL","source_id_and_acronym":"NCT06279611 - r/r B-NHL","lead_sponsor":"Shanghai Longyao Biotechnology Inc., Ltd.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LY007"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 12/25/2021","start_date":" 12/25/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-02-28"},{"id":"9a1bd20f-9971-453e-a407-90e121f47cfc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04697940","created_at":"2021-01-19T20:49:56.659Z","updated_at":"2024-07-02T16:35:20.405Z","phase":"Phase 1/2","brief_title":"Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL","source_id_and_acronym":"NCT04697940","lead_sponsor":"Han weidong","biomarkers":" BCL2 • CCND1 • BCL6","pipe":" | ","alterations":" Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative","tags":["BCL2 • CCND1 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • decitabine • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-02-07"},{"id":"b9c68d27-6990-4a0a-a0ac-3074641ed5c2","acronym":"MB106-CD20-001","url":"https://clinicaltrials.gov/study/NCT05360238","created_at":"2022-05-05T01:55:24.129Z","updated_at":"2024-07-02T16:35:25.644Z","phase":"Phase 1/2","brief_title":"Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL","source_id_and_acronym":"NCT05360238 - MB106-CD20-001","lead_sponsor":"Mustang Bio","biomarkers":" BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-106"],"overall_status":"Recruiting","enrollment":" Enrollment 287","initiation":"Initiation: 05/24/2022","start_date":" 05/24/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-12-20"},{"id":"8cc2ae4d-5542-474e-956c-f0147d922aa2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04007029","created_at":"2021-01-18T19:41:25.686Z","updated_at":"2024-07-02T16:35:34.403Z","phase":"Phase 1","brief_title":"Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT04007029","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" CD20 • CD8 • CD4","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 10/04/2019","start_date":" 10/04/2019","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2023-10-06"},{"id":"3f4c5428-51b9-428c-8b7e-591df451a815","acronym":"","url":"https://clinicaltrials.gov/study/NCT05768529","created_at":"2023-03-14T14:01:52.026Z","updated_at":"2024-07-02T16:35:36.640Z","phase":"Phase 1/2","brief_title":"Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05768529","lead_sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","biomarkers":" IL6","pipe":" | ","alterations":" CD20 positive • CD20 negative","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • U16"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-09-21"},{"id":"e8365d64-b203-4dd6-a740-efc6166c28db","acronym":"","url":"https://clinicaltrials.gov/study/NCT05094206","created_at":"2021-10-26T20:53:07.297Z","updated_at":"2024-07-02T16:35:39.176Z","phase":"Phase 1","brief_title":"CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies","source_id_and_acronym":"NCT05094206","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR20.19.22 T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-08-23"},{"id":"56c5cad0-d1ef-422d-be11-4bf042346cca","acronym":"","url":"https://clinicaltrials.gov/study/NCT05318963","created_at":"2022-04-08T20:52:42.049Z","updated_at":"2024-07-02T16:35:41.159Z","phase":"Phase 1","brief_title":"Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT05318963","lead_sponsor":"Qiu Lugui","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • LCAR-AIO"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2023-08-03"}]